"The US Food and Drug Administration (FDA) today approved etanercept-szzs (Erelzi, Sandoz), a biosimilar to etanercept (Enbrel, Amgen) for rheumatoid arthritis and other inflammatory diseases.
The biosimilar to etaner"...
CLINORIL (sulindac) is a non-steroidal anti-inflammatory drug (NSAID) that exhibits anti-inflammatory, analgesic and antipyretic activities in animal models. The mechanism of action, like that of other NSAIDs, is not completely understood but may be related to prostaglandin synthetase inhibition.
The extent of sulindac absorption from CLINORIL Tablets is similar as compared to sulindac solution.
There is no information regarding food effect on sulindac absorption. Antacids containing magnesium hydroxide 200 mg and aluminum hydroxide 225 mg per 5 mL have been shown not to significantly decrease the extent of sulindac absorption.
|Tmax||Age 19-41 (n=24)||Age 65-87 (n=12) 400 mg qd|
|(200 mg tablet)||2.54 ± 1.52 S|
|3.38 ± 2.30 S||5.75 ± 2.81 SF|
|4.88 ± 2.57 SP||6.83 ± 4.19 SP|
|4.96 ± 2.36 SF|
|(150 mg tablet)|
|3.90 ± 2.30 S|
|5.85 ±4.49 SP|
|6.15 ± 3.07 SF|
|Renal Clearance||200 mg tablet)|
|68.12 ± 27.56 mL/min S|
|36.58 ± 12.61 mL/min SP|
|150 mg tablet)|
|74.39 ± 34.15 mL/min S|
|41.75 ± 13.72 mL/min SP|
|Mean effective Half life(h)||7.8 S|
|S = Sulindac|
|SF = Sulindac Sulfide|
|SP = Sulindac Sulfone|
Sulindac, and its sulfone and sulfide metabolites, are 93.1, 95.4, and 97.9% bound to plasma proteins, predominantly to albumin. Plasma protein binding measured over a concentration range (0.5-2.0 μg/mL) was constant. Following an oral, radiolabeled dose of sulindac in rats, concentrations of radiolabel in red blood cells were about 10% of those in plasma. Sulindac penetrates the blood-brain and placental barriers. Concentrations in brain did not exceed 4% of those in plasma. Plasma concentrations in the placenta and in the fetus were less than 25% and 5% respectively, of systemic plasma concentrations. Sulindac is excreted in rat milk; concentrations in milk were 10 to 20% of those levels in plasma. It is not known if sulindac is excreted in human milk.
Sulindac undergoes two major biotransformations of its sulfoxide moiety: oxidation to the inactive sulfone and reduction to the pharmacologically active sulfide. The latter is readily reversible in animals and in man. These metabolites are present as unchanged compounds in plasma and principally as glucuronide conjugates in human urine and bile. A dihydroxydihydro analog has also been identified as a minor metabolite in human urine.
With the twice-a-day dosage regimen, plasma concentrations of sulindac and its two metabolites accumulate: mean concentration over a dosage interval at steady state relative to the first dose averages 1.5 and 2.5 times higher, respectively, for sulindac and its active sulfide metabolite.
Sulindac and its sulfone metabolite undergo extensive enterohepatic circulation relative to the sulfide metabolite in animals. Studies in man have also demonstrated that recirculation of the parent drug sulindac and its sulfone metabolite is more extensive than that of the active sulfide metabolite. The active sulfide metabolite accounts for less than six percent of the total intestinal exposure to sulindac and its metabolites.
Biochemical as well as pharmacological evidence indicates that the activity of sulindac resides in its sulfide metabolite. An in-vitro assay for inhibition of cyclooxygenase activity exhibited an EC50 of 0.02 μM for sulindac sulfide. In-vivo models of inflammation indicate that activity is more highly correlated with concentrations of the metabolite than with parent drug concentrations.
Approximately 50% of the administered dose of sulindac is excreted in the urine with the conjugated sulfone metabolite accounting for the major portion. Less than 1% of the administered dose of sulindac appears in the urine as the sulfide metabolite. Approximately 25% is found in the feces, primarily as the sulfone and sulfide metabolites.
The mean effective half-life (T½) is 7.8 and 16.4 hours, respectively, for sulindac and its active sulfide metabolite.
Because CLINORIL (sulindac) is excreted in the urine primarily as biologically inactive forms, it may possibly affect renal function to a lesser extent than other non-steroidal anti-inflammatory drugs; however, renal adverse experiences have been reported with CLINORIL (see ADVERSE REACTIONS).
In a study of patients with chronic glomerular disease treated with therapeutic doses of CLINORIL (sulindac) , no effect was demonstrated on renal blood flow, glomerular filtration rate, or urinary excretion of prostaglandin E2 and the primary metabolite of prostacyclin, 6-keto-PGF1α. However, in other studies in healthy volunteers and patients with liver disease, CLINORIL (sulindac) was found to blunt the renal responses to intravenous furosemide, i.e., the diuresis, natriuresis, increments in plasma renin activity and urinary excretion of prostaglandins. These observations may represent a differentiation of the effects of CLINORIL (sulindac) on renal functions based on differences in pathogenesis of the renal prostaglandin dependence associated with differing dose-response relationships of different NSAIDs to the various renal functions influenced by prostaglandins (see PRECAUTIONS).
In healthy men, the average fecal blood loss, measured over a two-week period during administration of 400 mg per day of CLINORIL (sulindac) , was similar to that for placebo, and was statistically significantly less than that resulting from 4800 mg per day of aspirin.
The pharmacokinetics of sulindac have not been investigated in pediatric patients.
Pharmacokinetic differences due to race have not been identified.
Patients with acute and chronic hepatic disease may require reduced doses of CLINORIL (sulindac) compared to patients with normal hepatic function since hepatic metabolism is an important elimination pathway.
Following a single dose, plasma concentrations of the active sulfide metabolite have been reported to be higher in patients with alcoholic liver disease compared to healthy normal subjects.
Sulindac pharmacokinetics have been investigated in patients with renal insufficiency. The disposition of sulindac was studied in end-stage renal disease patients requiring hemodialysis. Plasma concentrations of sulindac and its sulfone metabolite were comparable to those of normal healthy volunteers whereas concentrations of the active sulfide metabolite were significantly reduced. Plasma protein binding was reduced and the AUC of the unbound sulfide metabolite was about half that in healthy subjects.
Sulindac and its metabolites are not significantly removed from the blood in patients undergoing hemodialysis.
Since CLINORIL (sulindac) is eliminated primarily by the kidneys, patients with significantly impaired renal function should be closely monitored.
A lower daily dosage should be anticipated to avoid excessive drug accumulation.
In controlled clinical studies CLINORIL (sulindac) was evaluated in the following five conditions:
In patients with osteoarthritis of the hip and knee, the anti-inflammatory and analgesic activity of CLINORIL (sulindac) was demonstrated by clinical measurements that included: assessments by both patient and investigator of overall response; decrease in disease activity as assessed by both patient and investigator; improvement in ARA Functional Class; relief of night pain; improvement in overall evaluation of pain, including pain on weight bearing and pain on active and passive motion; improvement in joint mobility, range of motion, and functional activities; decreased swelling and tenderness; and decreased duration of stiffness following prolonged inactivity.
In clinical studies in which dosages were adjusted according to patient needs, CLINORIL (sulindac) 200 to 400 mg daily was shown to be comparable in effectiveness to aspirin 2400 to 4800 mg daily. CLINORIL (sulindac) was generally well tolerated, and patients on it had a lower overall incidence of total adverse effects, of milder gastrointestinal reactions, and of tinnitus than did patients on aspirin. (See ADVERSE REACTIONS.)
In patients with rheumatoid arthritis, the anti-inflammatory and analgesic activity of CLINORIL (sulindac) was demonstrated by clinical measurements that included: assessments by both patient and investigator of overall response; decrease in disease activity as assessed by both patient and investigator; reduction in overall joint pain; reduction in duration and severity of morning stiffness; reduction in day and night pain; decrease in time required to walk 50 feet; decrease in general pain as measured on a visual analog scale; improvement in the Ritchie articular index; decrease in proximal interphalangeal joint size; improvement in ARA Functional Class; increase in grip strength; reduction in painful joint count and score; reduction in swollen joint count and score; and increased flexion and extension of the wrist.
In clinical studies in which dosages were adjusted according to patient needs, CLINORIL (sulindac) 300 to 400 mg daily was shown to be comparable in effectiveness to aspirin 3600 to 4800 mg daily. CLINORIL (sulindac) was generally well tolerated, and patients on it had a lower overall incidence of total adverse effects, of milder gastrointestinal reactions, and of tinnitus than did patients on aspirin. (See ADVERSE REACTIONS.)
In patients with rheumatoid arthritis, CLINORIL (sulindac) may be used in combination with gold salts at usual dosage levels. In clinical studies, CLINORIL (sulindac) added to the regimen of gold salts usually resulted in additional symptomatic relief but did not alter the course of the underlying disease.
In patients with ankylosing spondylitis, the anti-inflammatory and analgesic activity of CLINORIL (sulindac) was demonstrated by clinical measurements that included: assessments by both patient and investigator of overall response; decrease in disease activity as assessed by both patient and investigator; improvement in ARA Functional Class; improvement in patient and investigator evaluation of spinal pain, tenderness and/or spasm; reduction in the duration of morning stiffness; increase in the time to onset of fatigue; relief of night pain; increase in chest expansion; and increase in spinal mobility evaluated by fingers-to-floor distance, occiput to wall distance, the Schober Test, and the Wright Modification of the Schober Test. In a clinical study in which dosages were adjusted according to patient need, CLINORIL (sulindac) 200 to 400 mg daily was as effective as indomethacin 75 to 150 mg daily. In a second study, CLINORIL (sulindac) 300 to 400 mg daily was comparable in effectiveness to phenylbutazone 400 to 600 mg daily. CLINORIL (sulindac) was better tolerated than phenylbutazone. (See ADVERSE REACTIONS.)
Acute painful shoulder (Acute subacromial bursitis/supraspinatus tendinitis)
In patients with acute painful shoulder (acute subacromial bursitis/supraspinatus tendinitis), the antiinflammatory and analgesic activity of CLINORIL (sulindac) was demonstrated by clinical measurements that included: assessments by both patient and investigator of overall response; relief of night pain, spontaneous pain, and pain on active motion; decrease in local tenderness; and improvement in range of motion measured by abduction, and internal and external rotation. In clinical studies in acute painful shoulder, CLINORIL (sulindac) 300 to 400 mg daily and oxyphenbutazone 400 to 600 mg daily were shown to be equally effective and well tolerated.
Acute gouty arthritis
In patients with acute gouty arthritis, the anti-inflammatory and analgesic activity of CLINORIL (sulindac) was demonstrated by clinical measurements that included: assessments by both the patient and investigator of overall response; relief of weight-bearing pain; relief of pain at rest and on active and passive motion; decrease in tenderness; reduction in warmth and swelling; increase in range of motion; and improvement in ability to function. In clinical studies, CLINORIL (sulindac) at 400 mg daily and phenylbutazone at 600 mg daily were shown to be equally effective. In these short-term studies in which reduction of dosage was permitted according to response, both drugs were equally well tolerated.
Last reviewed on RxList: 7/1/2010
This monograph has been modified to include the generic and brand name in many instances.
Additional Clinoril Information
Clinoril - User Reviews
Clinoril User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options